Thermo Fisher Scientific Continues Support for COVID-19 Testing on Historically Black College and University Campuses

- Thermo Fisher Scientific Inc., (NYSE:TMO) the world leader in serving science, today announced continuing support for The Just Project a national initiative to provide COVID-19 testing to students, faculty and staff across more than 60 historically black colleges and universities (HBCUs) at no cost. A $7.5 million commitment for the 2021-2022 school year will once again provide diagnostic instruments, test kits and related supplies.

HBCU Testing

"A year after we launched The Just Project, COVID-19 cases are increasing again, and testing is critical to ensuring campus safety," said Fred Lowery , senior vice president and president for customer channels at Thermo Fisher Scientific. "Last year HBCUs nationwide administered more than 50,000 tests under the project, and infection rates at participating schools were below 1% with minimal academic disruption. We hope other schools will join the program as we extend it through the 2021-2022 school year."

The Just Project, named after pioneering biologist Ernest Everett Just , has created a nationwide testing infrastructure with the capacity to provide free testing for all 107 HBCUs in the U.S. Currently, eight on-campus labs serve as hubs to process samples for more than 60 participating HBCUs. Testing hubs include Florida A&M University , Hampton University , Howard University College of Medicine, Meharry Medical College , Morehouse School of Medicine , Texas Southern University , Tuskegee University and Xavier University of Louisiana .

"The Just Project has made a significant difference on our campus," said Rashid Mosavin, Ph.D., dean of the College of Pharmacy and Health Sciences, Texas Southern University . "With testing available on our campus as frequently as needed, we were able to welcome our students, faculty and staff back to campus for in-person learning with confidence."

James E.K. Hildreth , M.D., Ph.D., president and CEO of Meharry Medical College said, "We're grateful for Thermo Fisher's continued support of COVID-19 testing across HBCUs to serve a broad reach of their students. Testing is the core component of a robust model in preventing the spread of infectious disease. With these resources and testing components in place, we're able to make data-driven decisions and policies to support the health and safety of our students and community."

Given the focus on recruiting diverse talent, Thermo Fisher has also committed to hiring more than 500 HBCU alumni over three years, reinforcing a commitment to create a more inclusive workplace. Since August of 2020, more than 180 HBCU alumni have joined the company.

For more information on The Just Project, please visit our website .

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $35 billion . Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com .

Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone:  781-622-1356
E-mail: rafael.tejada@thermofisher.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-continues-support-for-covid-19-testing-on-historically-black-college-and-university-campuses-301387537.html

SOURCE Thermo Fisher Scientific

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions Conference on Thursday, May 29, 2025 .

Geoff Martha , Medtronic chairman and chief executive officer, will make a formal presentation beginning at 11:00 a.m. EDT ( 10:00 a.m. CDT ). Immediately following the presentation, Martha will be joined by Thierry Piéton, Medtronic executive vice president and chief financial officer, to answer questions about the company.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Medtronic announces intent to separate Diabetes business

Medtronic announces intent to separate Diabetes business

Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies

Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

  • FDA Breakthrough Device Designation Awarded to AVIM Therapy
  • FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline.

Q1 2025 Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2025, which ended on Friday, April 25, 2025 .

Medtronic will host a video webcast at 7:00 a.m. CDT on May 21, 2025 , to discuss results for its fourth quarter and full fiscal year 2025. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

Star Jones , award winning television personality & women's heart health advocate,   helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign

A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their mother-figures. Despite cardiovascular disease being the #1 killer of women in the U.S. many women are still unaware of the risk and the importance of heart health.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×